Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enveric Biosciences, Inc.ENVB · Entity 8193 | Director | June 01, 2026 | June 03, 2026 |
| Theravance Biopharma, Inc.TBPH · Entity 5037 | SVP, CHIEF BUSINESS OFFICER | November 19, 2021 | November 24, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enveric Biosciences, Inc.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,423 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 18,518 · Balance 26,423 F1: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement.
Theravance Biopharma, Inc.
Report date November 19, 2021 · Filed November 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 429,783 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Tax withholding · Disposed 3,779 · Balance 429,783 F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:30 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 18,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001597334-26-000002 · ownership.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,423 F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 21:40 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 7,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337179 · ownership.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,904 F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in accordance with the terms and conditions of the Plan and the reporting person's restricted stock award agreement. F2 · balance_after: On January 29, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 15 shares of issued and outstanding common stock were reclassified as one share of common stock (the "January Reverse Stock Split"). On October 28, 2025, the common stock of the Issuer began trading on a split-adjusted basis, pursuant to which every 12 shares of issued and outstanding common stock were reclassifed as one share of common stock (the"October Reverse Stock Split" together with the January Reverse Stock Split, the "Reverse Stock Splits"). The number of securities reported in this Form 4 has been adjusted to reflect the Reverse Stock Splits. Read SEC document |
| October 09, 2024 Filed Oct 11, 2024 23:14 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | GrantCommon Stock | 47,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025055 · form4-10112024_111008.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,733 F1 · shares: Represents restricted stock granted to the reporting person pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended (the "Plan"). Such shares shall vest in full on December 31, 2024, subject to the terms and conditions of the Plan and the reporting person's restricted stock award agreement. Read SEC document |
| September 15, 2023 Filed Sep 19, 2023 21:34 UTC | Enveric Biosciences, Inc. ENVB · Entity 8193 | PurchaseCommon Stock | 1,000 | $2.14 | $2,140.00 |
DisclosureSEC source: 0001415889-23-013430 · form4-09192023_090952.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| November 19, 2021 Filed Nov 24, 2021 01:25 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,779 | $8.36 | $31,592.44 |
DisclosureSEC source: 0001415889-21-005470 · form4-11232021_051132.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,783 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 22:57 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,779 | $14.05 | $53,094.95 |
DisclosureSEC source: 0001179110-21-008396 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,562 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2021 Filed May 24, 2021 22:12 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,779 | $17.80 | $67,266.20 |
DisclosureSEC source: 0001179110-21-005844 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,341 F1 · balance_after: Includes 1,401 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 14, 2021. Read SEC document |
| February 20, 2021 Filed Feb 23, 2021 23:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 26,961 | $18.79 | $506,597.19 |
DisclosureSEC source: 0001179110-21-002164 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,719 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:45 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001537 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,680 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 23:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,214 | $17.21 | $72,522.94 |
DisclosureSEC source: 0001179110-20-011369 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,680 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 22:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,214 | $18.22 | $76,779.08 |
DisclosureSEC source: 0001179110-20-009267 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,894 Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,214 | $26.67 | $112,387.38 |
DisclosureSEC source: 0001179110-20-006526 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,108 F1 · balance_after: Includes 1,402 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2020. Read SEC document |
| February 20, 2020 Filed Feb 25, 2020 00:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 24,392 | $25.90 | $631,752.80 |
DisclosureSEC source: 0001179110-20-002148 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,920 Read SEC document |
| February 03, 2020 Filed Feb 6, 2020 00:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001202 · edgar.xml · nonDerivative · entry 2 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,312 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 3, 2020, the performance conditions applicable to 54,000 shares were achieved and such shares will vest on February 20, 2021, subject to the reporting person's continued service. Read SEC document |
| February 03, 2020 Filed Feb 6, 2020 00:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001202 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,312 Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 23:22 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,447 | $17.60 | $43,067.20 |
DisclosureSEC source: 0001179110-19-012015 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,312 Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 22:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,335 | $21.51 | $50,225.85 |
DisclosureSEC source: 0001179110-19-009790 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,759 Read SEC document |
| May 20, 2019 Filed May 22, 2019 22:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 1,604 | $19.84 | $31,823.36 |
DisclosureSEC source: 0001179110-19-006524 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,094 F1 · balance_after: Includes 1,027 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2019. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:16 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,919 | $27.00 | $132,813.00 |
DisclosureSEC source: 0001179110-19-002418 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,671 Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 22:46 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 47,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001564 · edgar.xml · nonDerivative · entry 2 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,590 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 5, 2019, the performance conditions applicable to 47,250 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 22:46 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001564 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,340 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 22:45 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,735 | $24.79 | $142,170.65 |
DisclosureSEC source: 0001179110-18-013108 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,340 Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 23:33 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,735 | $26.95 | $154,558.25 |
DisclosureSEC source: 0001179110-18-010820 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,075 Read SEC document |
| May 20, 2018 Filed May 22, 2018 23:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 18,424 | $24.31 | $447,887.44 |
DisclosureSEC source: 0001179110-18-007373 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,810 Read SEC document |
| May 14, 2018 Filed May 16, 2018 23:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006937 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,234 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On May 14, 2018, the performance conditions applicable to 33,750 shares were achieved and such shares will vest on May 20, 2018. F2 · balance_after: Includes 865 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:40 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,741 | $29.09 | $137,915.69 |
DisclosureSEC source: 0001179110-18-002610 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,619 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:21 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002124 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,360 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 21:38 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,820 | $28.58 | $166,335.60 |
DisclosureSEC source: 0001179110-17-014564 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,360 Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 21:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | PurchaseOrdinary Shares | 4,000 | $26.34 | $105,358.80 |
DisclosureSEC source: 0001179110-17-011785 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,180 F1 · price: Represents the weighted average purchase price per share for the open market purchase on August 21, 2017. The shares were purchased at prices ranging from $26.2499 to $26.4541 per share. Full information regarding the number of shares purchased at each price shall be provided upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 20, 2017 Filed Aug 22, 2017 22:29 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,820 | $27.40 | $159,468.00 |
DisclosureSEC source: 0001179110-17-011749 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,180 Read SEC document |
| May 20, 2017 Filed May 24, 2017 00:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,820 | $36.83 | $214,350.60 |
DisclosureSEC source: 0001179110-17-007879 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP, Chief Comm Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 F1 · balance_after: Includes 1,702 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 15, 2017. Read SEC document |
| February 20, 2017 Filed Feb 23, 2017 00:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,762 | $33.78 | $295,980.36 |
DisclosureSEC source: 0001179110-17-002992 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP Global Head Acute Care Bus 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,118 Read SEC document |
| February 06, 2017 Filed Feb 9, 2017 00:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002000 · edgar.xml · nonDerivative · entry 1 PASQUALONE FRANK · CIK 0001597334 · SVP Global Head Acute Care Bus 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,880 F1 · balance_after: Includes 1,702 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on May 13, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.